Should I buy or sell Palatin Technologies stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PTN shares. View PTN analyst ratings or view top-rated stocks .

What is Palatin Technologies' stock price target for 2024?

1 analysts have issued 1 year target prices for Palatin Technologies' shares. Their PTN share price targets range from $17.00 to $17.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 818.9% from the stock's current price. View analysts price targets for PTN or view top-rated stocks among Wall Street analysts .

How have PTN shares performed in 2024?

Palatin Technologies' stock was trading at $4.00 on January 1st, 2024. Since then, PTN shares have decreased by 53.8% and is now trading at $1.85. View the best growth stocks for 2024 here .

Are investors shorting Palatin Technologies?

Palatin Technologies saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,450,000 shares, an increase of 25.0% from the February 29th total of 1,160,000 shares. Based on an average trading volume of 552,700 shares, the days-to-cover ratio is presently 2.6 days. Currently, 9.4% of the company's stock are sold short. View Palatin Technologies' Short Interest .

When is Palatin Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our PTN earnings forecast .

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.36. The biopharmaceutical company earned $2.03 million during the quarter, compared to the consensus estimate of $2.28 million. Palatin Technologies had a negative net margin of 445.12% and a negative trailing twelve-month return on equity of 583.06%. During the same quarter in the prior year, the company earned ($0.13) earnings per share.

When did Palatin Technologies' stock split?

Palatin Technologies shares reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX) , Sorrento Therapeutics (SRNE) , Trevena (TRVN) , Alliqua Biomedical (ALQA) , Catalyst Pharmaceuticals (CPRX) , AVEO Pharmaceuticals (AVEO) , ImmunoGen (IMGN) , TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM) .

How do I buy shares of Palatin Technologies?

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:PTN

Palatin Technologies (PTN) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free PTN Stock Alerts

$1.84

-0.05 (-2.65%)

(As of 04:38 PM ET)

Compare

Today's Range: $1.84
▼
$1.95
50-Day Range: N/A
52-Week Range: $1.43
▼
$5.65

Volume: 154,666 shs
Average Volume: 643,438 shs
Market Capitalization: $29.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

Get Palatin Technologies alerts:

Palatin Technologies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 818.9% Upside
$17.00 Price Target
Short Interest: Bearish
9.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.46
Based on 2 Articles This Week
Insider Trading: Selling Shares
$23,400 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.36) to ($0.66) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.52 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Palatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Palatin Technologies has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.45% of the float of Palatin Technologies has been sold short.
Short Interest Ratio / Days to Cover
Palatin Technologies has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Palatin Technologies has recently increased by 0.69%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Palatin Technologies does not currently pay a dividend.
Dividend Growth
Palatin Technologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PTN.

1.4

News and Social Media Coverage

News Sentiment
Palatin Technologies has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Palatin Technologies this week, compared to 2 articles on an average week.
Search Interest
Only 24 people have searched for PTN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Palatin Technologies insiders have sold 83.96% more of their company's stock than they have bought. Specifically, they have bought $12,720.00 in company stock and sold $23,400.00 in company stock.
Percentage Held by Insiders
Only 7.70% of the stock of Palatin Technologies is held by insiders.
Percentage Held by Institutions
Only 11.50% of the stock of Palatin Technologies is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Palatin Technologies are expected to grow in the coming year, from ($2.36) to ($0.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Palatin Technologies is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Palatin Technologies is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Palatin Technologies has a P/B Ratio of 185.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

Click here to learn more >>>

About Palatin Technologies Stock (NYSEAMERICAN:PTN)

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

PTN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PTN Stock News Headlines

April 12, 2024 | insidertrades.com

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Purchases $12,720.00 in Stock

April 19, 2024 | americanbankingnews.com

Palatin Technologies (NYSEAMERICAN:PTN) Stock Price Crosses Above 200 Day Moving Average of $0.00

April 19, 2024 | Behind the Markets (Ad)

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

April 14, 2024 | americanbankingnews.com

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) Director Buys $12,720.00 in Stock

April 12, 2024 | msn.com

Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying

April 10, 2024 | americanbankingnews.com

Palatin Technologies (NYSEAMERICAN:PTN) Shares Pass Above 200-Day Moving Average of $0.00

April 8, 2024 | marketwatch.com

Palatin Technologies Shares Rise 27% After Positive Trial Results for PL9643

April 8, 2024 | finance.yahoo.com

Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data

April 19, 2024 | Behind the Markets (Ad)

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

April 8, 2024 | msn.com

Galectin Therapeutics, Titan Pharmaceuticals, Outset Medical among healthcare movers

April 8, 2024 | msn.com

Palatin stock jumps 16% on positive Phase 3 data for eye drug

April 8, 2024 | markets.businessinsider.com

Palatin Says Topline Results From The Phase 3 MELODY-1 Study Of PL9643 In Dry Eye Disease Positive

April 8, 2024 | finance.yahoo.com

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

March 15, 2024 | finance.yahoo.com

PTN Apr 2024 2.500 put

March 15, 2024 | finance.yahoo.com

PTN Apr 2024 7.500 call

March 14, 2024 | msn.com

Palatin files to sell 1.92M shares of common stock for holders

February 29, 2024 | markets.businessinsider.com

Maintained Buy Rating on Palatin Technologies Amid Promising Clinical Results and Future Prospects

February 28, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Palatin Technologies (PTN) and G1 Therapeutics (GTHX)

February 28, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Opko Health (OPK)

February 28, 2024 | msn.com

Palatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock Plummets

February 28, 2024 | finanznachrichten.de

Palatin Technologies, Inc.: Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

February 28, 2024 | marketwatch.com

Palatin Technologies Shares Tumble Premarket on Dry-Eye Study Results

February 28, 2024 | finance.yahoo.com

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

February 28, 2024 | prnewswire.com

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

February 21, 2024 | finance.yahoo.com

Palatin Technologies, Inc. (PTN)

February 16, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Palatin Technologies for Promising Pipeline and Strategic Market Positioning

February 16, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Palatin Technologies Amid Promising Clinical Trials and Robust Financial Position

See More Headlines

Receive PTN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:PTN
Previous Symbol: NYSE:PTN
CUSIP: N/A
CIK: 911216
Web: www.palatin.com
Phone: (609) 495-2200
Fax: 609-495-2202
Employees: 34
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.00
High Stock Price Target: $17.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +771.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,540,000.00
Net Margins: -445.12%
Pretax Margin: -503.33%
Return on Equity: -583.06%
Return on Assets: -184.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.09
Quick Ratio: 1.09

Sales & Book Value

Annual Sales: $4.85 million
Price / Sales: 6.49
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.01 per share
Price / Book: 195.00

Miscellaneous

Outstanding Shares: 16,140,000
Free Float: 14,894,000
Market Cap: $31.47 million
Optionable: Not Optionable
Beta: 0.93

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Carl Spana Ph.D. (Age 62)
Co-Founder, President, CEO & Director
Comp: $979k
Mr. Stephen T. Wills CPA (Age 67)
MST, CFO, COO, Executive VP, Treasurer & Secretary
Comp: $910.55k
Burns McClellan
Vice President of Investor Relations
Mr. Stephen A. Slusher Esq.
Chief Legal Officer
Dr. Michael B. Raizman M.D.
Chief Medical Officer
Mr. James E. Hattersley (Age 64)
Senior Vice President of Business Development
Mr. John Dodd Ph.D.
Senior Vice President of Preclinical Development
Mr. Robert Jordan
Senior Vice President of Program Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PTN Stock Analysis - Frequently Asked Questions

Should I buy or sell Palatin Technologies stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PTN shares.
View PTN analyst ratings or view top-rated stocks.
What is Palatin Technologies' stock price target for 2024?: 1 analysts have issued 1 year target prices for Palatin Technologies' shares. Their PTN share price targets range from $17.00 to $17.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 818.9% from the stock's current price.
View analysts price targets for PTN or view top-rated stocks among Wall Street analysts.
How have PTN shares performed in 2024?: Palatin Technologies' stock was trading at $4.00 on January 1st, 2024. Since then, PTN shares have decreased by 53.8% and is now trading at $1.85.
View the best growth stocks for 2024 here.
Are investors shorting Palatin Technologies?: Palatin Technologies saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,450,000 shares, an increase of 25.0% from the February 29th total of 1,160,000 shares. Based on an average trading volume of 552,700 shares, the days-to-cover ratio is presently 2.6 days. Currently, 9.4% of the company's stock are sold short.
View Palatin Technologies' Short Interest.
When is Palatin Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our PTN earnings forecast.

How were Palatin Technologies' earnings last quarter?: Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.36. The biopharmaceutical company earned $2.03 million during the quarter, compared to the consensus estimate of $2.28 million. Palatin Technologies had a negative net margin of 445.12% and a negative trailing twelve-month return on equity of 583.06%. During the same quarter in the prior year, the company earned ($0.13) earnings per share.
When did Palatin Technologies' stock split?: Palatin Technologies shares reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Palatin Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).
How do I buy shares of Palatin Technologies?: Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:PTN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Palatin Technologies (PTN) Stock Price, News & Analysis

Palatin Technologies MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Palatin Technologies Stock (NYSEAMERICAN:PTN)

PTN Stock Price History

PTN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PTN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™